Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of Prolia in glucocorticoid-induced osteoporosis in mainland China
CTR20250007Phase 4Active
- Sponsor
- Amgen
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of denosumab in glucocorticoid-induced osteoporosis (GIOP), sponsored by Amgen. Started May 2025; status: active.
02
Drugs
denosumab
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on CTR20250007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250007.